Menu UF Health Home Menu
 

Pharmacokinetics


Peloquin_Charles

Charles Peloquin, Pharm.D., FCCP

Title: Professor, and Director, Infectious Disease Pharmacokinetics Lab
College/Institute: Pharmacy and Medicine, Emerging Pathogens Institute
Research Interests: therapeutic drug monitoring; treatments for serious infections

Faculty Profile


The Infectious Disease Pharmacokinetics Laboratory at the University of Florida (IDPL) is focused clinically on the treatment of patients with serious infections, including tuberculosis, HIV, and fungal infections. The IDPL provides therapeutic drug monitoring using high-performance liquid chromatography (HPLC) and gas chromatography (GC). Therapeutic drug monitoring (TDM) is a well-established clinical tool, and the IDPL focuses on drug assays that most other clinical labs do not offer.  For 25 years, the IDPL has individualized patients’ drug regimens by monitoring serum drug concentrations and interpreting the results. Interpretations are based upon many years of clinical experience with these types of patients, allowing health care practitioners to confidently make dose adjustments.

TDM allows clinicians to assess each patient’s pharmacokinetics (drug absorption, distribution, metabolism, and clearance). TDM also allows clinicians to pull apart complex drug-drug interactions, and to arrive at the needed doses for each drug. Tuberculosis is a major focus of the IDPL, but we also serve patients with serious bacterial and fungal infections, people living with HIV, and those patients who acquire opportunistic infections. We also have considerable experience with patients infected with non-tuberculous mycobacterial (NTM) infections.

This process allows Peloquin’s  team to assess each patient’s ability to absorb, metabolize and excrete drugs, which then enables him to recommend customized drug dosages based upon these pharmacokinetic factors as well as the severity of the patient’s infection. Tuberculosis is a major focus of the IDPL, but they also develop drug regimens for cancer patients who develop serious fungal infections, people who are HIV-positive and acquire secondary opportunistic infections, patients with non-TB mycobacterial infections, or people who do not absorb their medication well because of underlying conditions.

The IDPL also serves as a national reference center for the determination of serum concentrations for the antimycobacterial, antifungal, and anti-HIV drugs, as well as linezolid. His research efforts focus on therapeutic drug monitoring and clinical trials for patients with advanced mycobacterial diseases.